Provided are a condensed cyclic compound and an organic light-emitting device including the same. The organic light-emitting device may include a first electrode, a second electrode, and an organic layer disposed between the first electrode and the second electrode. The organic layer may include the condensed cyclic compound represented by Formula 1: ##STR00001## In Formula 1, rings A.sub.1, A.sub.2, and A.sub.3 may each be independently a C.sub.5-C.sub.60 carbocyclic group or a C.sub.2-C.sub.30 heterocyclic group, and n1 to n3 may each be independently 0 or 1, provided that the sum of n1, n2, and n3 is 1. In addition, the descriptions of X.sub.1, L.sub.1 to L.sub.9, a1 to a9, Ar.sub.1 to Ar.sub.6, b1 to b6, R.sub.1 to R.sub.3, and c1 to c3 are as defined in the present specification.

The present specification relates to an organic light emitting device comprising a first electrode, a second electrode, and an organic material layer comprising one or more layers provided between the first electrode and the second electrode, wherein the one or more layers of the organic material layer comprise a heterocyclic compound represented by Chemical Formula 1 and a heterocyclic compound represented by Chemical Formula 2, a composition for the organic material layer of the organic light emitting device, and a method for manufacturing the organic light emitting device.

A substituted thiazole aromatic ring compound and a preparation method therefor, a herbicidal composition and use thereof. The substituted thiazole aromatic ring compound is as shown in general formula I:

##STR00001##

Wherein, Y represents halogen, halogenated alkyl, cyano, nitro or amino; Q represents

##STR00002##

M represents CH or N; X represents

##STR00003##

X.sub.1 represents O or S; X.sub.2 represents OX.sub.3, SX.sub.3 or N(X.sub.3).sub.2. The compound has excellent herbicidal activity against gramineous weeds, broadleaf weeds, and so on even at low application rates, and has high selectivity for crops.

A pharmaceutical containing a compound having an agonist activity for LPA3 as an active ingredient, wherein the compound is of formula (IY):

##STR00001##

wherein all symbols represent the same meaning as described in the specification, and which is useful as a preventive and/or therapeutic agent for, e.g., essential thrombocythemia or reactive thrombocytosis.

The invention provides glucocorticoid receptor antagonists for treatment of infection, neoplasia, and fatty liver disease.

Provided are a heterocyclic compound represented by Formula 1, an organic light-emitting device including the same, and an electronic apparatus including the organic light-emitting device.

##STR00001##

The detailed description of Formula 1 is the same as described in the present specification.

Provided are boron substituted organometallic compounds of Formula I:

##STR00001##

Also provided are formulations including these organometallic compounds. Further provided are OLEDs and related consumer products that utilize these organometallic compounds.

The present specification relates to a compound of Formula 1, a coating composition including the compound, an organic light emitting device formed by using the coating composition, and a manufacturing method thereof.

A compound of Formula I: ##STR00001##
wherein: X.sup.1-X.sup.8 are each independently C or N, wherein two adjacent X.sup.1-X.sup.8 are carbon-fused to a structure of Formula II: ##STR00002## X.sup.9-X.sup.12 are each independently C or N; A.sup.1, A.sup.2, and A.sup.3 are each independently selected from the group consisting of O, S, Se, N, NR, CR, CRR′, SiR, SiRR′, GeR, and GeRR′, with at least one of A.sup.1 and A.sup.2 being N or NR; each occurrence of is independently a single bond or a double bond, wherein one occurrence of is a single bond and one occurrence of is a double bond; each of R.sup.A, R.sup.B, and R.sup.c independently represents zero, mono, or up to a maximum allowed substitution to its associated ring; each of occurrence R, R′, R.sup.A, R.sup.B, and R.sup.C is independently a hydrogen or a substituent selected from the group consisting of Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, Formula IX, deuterium, halogen, alkyl, cycloalkyl, heteroalkyl, heterocycloalkyl, arylalkyl, alkoxy, aryloxy, amino, silyl, boryl, alkenyl, cycloalkenyl, heteroalkenyl, alkynyl, aryl, heteroaryl, acyl, carboxylic acid, ether, ester, nitrile, isonitrile, sulfanyl, sulfinyl, sulfonyl, phosphino, and combinations thereof, with at least one of R, R′, R.sup.A, R.sup.B, and R.sup.C comprising a group of Formula III, Formula IV, Formula V, Formula VI, Formula VII, Formula VIII, or Formula IX: ##STR00003## ##STR00004## each occurrence of Y.sup.1, Y.sup.2, and Y.sup.3 is independently absent, O, S, Se, NR, CRR′, SiRR′, or GeRR′; each occurrence of Ar.sup.1, and Ar.sup.2 is independently an optionally substituted aryl group or an optionally substituted heteroaryl group, wherein Ar.sup.1 and Ar.sup.2 are optionally joined or fused together to form a ring; each occurrence of X.sup.13-X.sup.20 is independently C or N, with the proviso that at least one of X.sup.13-X.sup.20 is N; each occurrence of A.sup.4 is selected from the group consisting of O, S, Se, NR, CRR′, SiRR′, and GeRR′; each occurrence of R.sup.X independently represents zero, mono, or up to a maximum allowed substitution to its associated ring; each occurrence of R.sup.X is in

Embodiments provide a cyclic compound, a light-emitting device including the cyclic compound, and an electronic apparatus including the light-emitting device. The light-emitting device includes a first electrode, a second electrode facing the first electrode, an interlayer between the first electrode and the second electrode and including an emission layer; and at least one cyclic compound. The cyclic compound is represented by Formula 1:

##STR00001##

The description of Formula 1 is provided in the specification.